Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Clinical trial NCT05043090 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05043090
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Papillary Renal Cell Carcinoma

Start date: 2021-10-28
Primary completion: 2025-12-31
Enrollment: 148

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.